<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>American College of Medical Genetics and Genomics (ACMG) list of genes for which secondary findings should be disclosed</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">American College of Medical Genetics and Genomics (ACMG) list of genes for which secondary findings should be disclosed</h1>
<div class="graphic"><div class="figure"><div class="ttl">American College of Medical Genetics and Genomics (ACMG) list of genes for which secondary findings should be disclosed</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup> <colgroup span="2" width="40%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Disease category</td> <td class="subtitle1">Syndrome</td> <td class="subtitle1">Gene(s)</td> </tr> <tr> <td class="divider_bottom" rowspan="6">Cancer</td> <td>Breast and ovarian cancer</td> <td><em>BRCA1</em>, <em>BRCA2</em>, <em>PALB2</em><sup>Δ</sup></td> </tr> <tr> <td>Li-Fraumeni syndrome, Peutz-Jeghers syndrome; Juvenile polyposis, and PTEN hamartoma syndrome</td> <td><em>BMPR1A</em><sup>*</sup>, <em>PTEN</em>, <em>SMAD4</em><sup>*</sup>, <em>STK11</em>, <em>TP53</em></td> </tr> <tr> <td>Familial adenomatous polyposis, Lynch syndrome, and MYH-associated polyposis</td> <td><em>APC</em>, <em>MLH1</em>, <em>MSH2</em>, <em>MSH6</em>, <em>MUTYH</em>, <em>PMS2</em></td> </tr> <tr> <td>Retinoblastoma, tuberous sclerosis, Von Hippel Lindau syndrome, Wilms tumor</td> <td><em>RB1</em>, <em>TSC1</em>, <em>TSC2</em>, <em>VHL</em>, <em>WT1</em></td> </tr> <tr> <td>Multiple endocrine neoplasia 1 or 2 and familial medullary thyroid cancer</td> <td><em>MEN1</em>, <em>RET</em></td> </tr> <tr class="divider_bottom"> <td>Hereditary paraganglionoma-pheochromocytoma syndrome and neurofibromatosis type 2</td> <td><em>MAX</em><sup>Δ</sup>, <em>NF2</em>, <em>SDHAF2</em>, <em>SDHB</em>, <em>SDHC</em>, <em>SDHD</em>, <em>TMEM127</em><sup>Δ</sup></td> </tr> <tr> <td class="divider_bottom" rowspan="3">Cardiovascular disease</td> <td>Hypertrophic or dilated cardiomyopathy</td> <td><em>ACTC1</em>, <em>BAG3</em><sup>Δ</sup>, <em>DES</em><sup>Δ</sup>, <em>FLNC</em>, <em>GLA</em>, <em>LMNA</em>, <em>MYBPC3</em>, <em>MYH7</em>, <em>MYL2</em>, <em>MYL3</em>, <em>PRKAG2</em>, <em>RBM20</em><sup>Δ</sup>, <em>TNNC1</em><sup>Δ</sup>, <em>TNNI3</em>, <em>TNNT2</em>, <em>TPM1</em>, <em>TTN</em></td> </tr> <tr> <td>Catecholaminergic polymorphic VT, arrhythmogenic right ventricular cardiomyopathy, Long QT syndromes, and Brugada syndrome</td> <td><em>CALM1</em><sup>Δ</sup>, <em>CALM2</em><sup>Δ</sup>, <em>CALM3</em><sup>Δ</sup>, <em>CASQ2</em><sup>Δ</sup>, <em>DSC2</em>, <em>DSG2</em>, <em>DSP</em>, <em>KCNH2</em>, <em>KCNQ1</em>, <em>PKP2</em>, <em>RYR2</em>, <em>SCN5A</em>, <em>TMEM43</em>, <em>TRDN</em><sup>Δ</sup></td> </tr> <tr class="divider_bottom"> <td>Familial hypercholesterolemia</td> <td><em>APOB</em>, <em>LDLR</em>, <em>PCSK9</em></td> </tr> <tr> <td class="divider_bottom" rowspan="3">Connective tissue or vascular integrity</td> <td>Ehlers-Danlos syndrome (vascular type)</td> <td><em>COL3A1</em></td> </tr> <tr> <td>Hereditary hemorrhagic telangiectasia</td> <td><em>ACVRL1</em><sup>Δ</sup>, <em>ENG</em><sup>Δ</sup></td> </tr> <tr class="divider_bottom"> <td>Marfan syndrome, Loeys-Dietz syndrome, and familial thoracic aortic aneurysms and dissections</td> <td><em>ACTA2</em>, <em>FBN1</em>, <em>MYH11</em><sup>¶</sup>, <em>SMAD3</em>, <em>TGFBR1</em>, <em>TGFBR2</em></td> </tr> <tr class="divider_bottom"> <td>Malignant hyperthermia sensitivity</td> <td> </td> <td><em>CACNA1S</em>, <em>RYR1</em></td> </tr> <tr> <td class="divider_bottom" rowspan="5">Metabolism</td> <td>Wilson disease (copper metabolism)</td> <td><em>ATP7B</em><sup>*</sup></td> </tr> <tr> <td>Biotinidase deficiency</td> <td><em>BTD</em><sup>Δ</sup></td> </tr> <tr> <td>Fabry disease</td> <td><em>GLA</em></td> </tr> <tr> <td>Pompe disease</td> <td><em>GAA</em><sup>Δ</sup></td> </tr> <tr class="divider_bottom"> <td>Ornithine transcarbamylase deficiency (urea cycle)</td> <td><em>OTC</em><sup>*</sup></td> </tr> <tr> <td rowspan="4">Others</td> <td>Hereditary hemochromatosis</td> <td><em>HFE</em><sup>Δ</sup></td> </tr> <tr> <td>Maturity-onset diabetes of the young</td> <td><em>HNF1A</em><sup>Δ</sup></td> </tr> <tr> <td>Retinopathy</td> <td><em>RPE65</em><sup>Δ</sup></td> </tr> <tr> <td>Hereditary amyloidosis</td> <td><em>TTR</em><sup>Δ</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">This list includes genes identified by the American College of Medical Genetics and Genomics (ACMG) as clinically actionable when known pathogenic (and, in some cases, expected pathogenic) variants are identified by whole genome or exome sequencing. Refer to UpToDate topics on genetic counseling and secondary findings from genomic testing for further details. An updated list is maintained on the ClinVar website (<a href="http://www.ncbi.nlm.nih.gov/clinvar/docs/acmg/" target="_blank">https://www.ncbi.nlm.nih.gov/clinvar/docs/acmg/</a>).</div><div class="graphic_footnotes"><p>ACMG: American College of Medical Genetics and Genomics; VT: ventricular tachycardia.</p>
<p>* Added in the 2016 revision (ACMG 2.0).</p>
<p>¶ <em>MYLK</em> was removed in the 2016 revision due to lack of an effective confirmatory test or intervention to improve outcomes.</p>
Δ Added in the 2023 revision (ACMG 3.0 to 3.2).</div><div class="graphic_reference">Prepared with data from:
<ol>
<li>Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15:565.</li>
<li>Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): A policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017; 19:249.</li>
<li>Miller DT, Lee K, Abul-Husn NS, et al. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2023; 25:100866.</li>
</ol></div><div id="graphicVersion">Graphic 97842 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
